Adaptimmune Therapeutics (ADAP) AI Stock Analysis

• Market Cap: $70.42M
• Dividend Yield: N/A
• Average Volume (3M): 589.37K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.57
• Revenue Growth: 883.05%
• EPS Growth: 62.93%
• Country: US
• Employees: 506
• Sector: Healthcare
• Sector Strength: 40
• Industry: Biotechnology
• EPS (TTM): -0.03
• Shares Outstanding: 265,051,600
• 10 Day Avg. Volume: 502,209
• 30 Day Avg. Volume: 589,369
• PEG Ratio: -0.15
• Price to Book (P/B): -1.93
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.66
• Enterprise Value/Market Cap: 0.78
• Enterprise Value/Revenue: 0.08
• Enterprise Value/Gross Profit: 0.31
• Enterprise Value/Ebitda: -0.25
• 1Y Price Target: $1.39
• Price Target Upside: 379.31% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 7

• Rating: 47 Neutral
• Price Target: $0.50 ▲(72.41%Upside)

The overall score is driven primarily by the significant financial risks, including persistent losses and negative equity, which weigh heavily despite revenue growth. Technical analysis provides some positive signals, but valuation remains a challenge with negative earnings. The earnings call adds a modestly positive outlook due to operational successes.

Positive Factors

Financial Performance

Management anticipates full-year 2025 Tecelra revenue of $35-45M, surpassing the previous sellside consensus estimate of $25M.

Product Launch

The launch of Tecelra is gaining momentum with strong sales and increasing patient treatment numbers.

Negative Factors

Financial Challenges

Management has expressed doubts about their ability to remain operational.

Market Concerns

Concerns around loan repayment and a depressed biotech market are impacting the company's outlook.

Adaptimmune Therapeutics Business Overview & Revenue Model

Company Description

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4 that is in phase II clinical trials with SPEARHEAD-1 for synovial sarcoma and myxoid round cell liposarcoma indications (MRCLS); in phase II clinical trials with SPEARHEAD-2 for patients with head and neck cancer; and in phase I clinical trials for urothelial, melanoma, head and neck, ovarian, non-small cell lung, esophageal and gastric, synovial sarcoma, and MRCLS cancers. The company is also developing ADP-A2AFP, which is in phase I clinical trials for hepatocellular carcinoma; and ADP-A2M4CD8, which is in phase I clinical trial for SPEAR T-cells focusing on treating patients with lung, gastroesophageal, head and neck, ovarian, and bladder cancers. It has a collaboration and license agreement with GSK; third party collaborations with Noile-Immune Biotech Inc., Alpine Immune Sciences, Inc., and National Center for Cancer Immune Therapy in Denmark; strategic alliance agreement with the MD Anderson Cancer Center; and co-development and co-commercialization agreement with Universal Cells, Inc. Adaptimmune Therapeutics plc also has a strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic T-cell therapies utilizing aß T-cell receptors. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.

How the Company Makes Money

Adaptimmune Therapeutics generates revenue primarily through collaborations, partnerships, and licensing agreements with other pharmaceutical and biotechnology companies. These agreements often involve upfront payments, milestone payments based on the achievement of specific development, regulatory, and sales objectives, and royalties on future product sales. Additionally, the company may receive funding and grants from government bodies and research institutions to support its research and development activities. These revenue streams are crucial to funding the development and commercialization of its proprietary T-cell therapies.

Adaptimmune Therapeutics Financial Statement Overview

Summary

Adaptimmune Therapeutics shows significant revenue growth, but persistent losses, negative equity, and weak cash flows highlight substantial financial risks. The company's financial health is compromised by high operational costs and liabilities, requiring strategic measures to improve profitability and liquidity.

Income Statement

Adaptimmune Therapeutics shows a significant improvement in revenue over the years, with a recent TTM revenue of $179.6M compared to $3.96M in 2020. However, the company consistently reports negative EBIT and net income, reflecting ongoing challenges in managing operational costs and achieving profitability. Gross profit margins have improved, but the net profit margin remains negative, indicating continued losses. Despite revenue growth, profitability concerns significantly impact the score.

Balance Sheet

The company's balance sheet reveals high financial risk, with negative stockholders' equity in the latest TTM, indicating liabilities exceed assets. The debt-to-equity ratio is unfavorable due to negative equity, and the return on equity is also negative, reflecting ongoing losses. Cash reserves have declined, adding to financial instability. The company's high liabilities and negative equity present substantial financial risks.

Cash Flow

Cash flow analysis shows negative operating and free cash flows, indicating the company's operations are not generating cash. The free cash flow growth rate is negative, suggesting increased cash consumption. The operating cash flow to net income ratio is unfavorable, reflecting inefficiencies in cash generation relative to reported losses. Despite some financing inflows, the cash flow position remains weak, impacting stability.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	179.64M	178.03M	60.28M	27.15M	6.15M	3.96M
Gross Profit	176.16M	177.96M	50.42M	-100.58M	-104.94M	-87.61M
EBITDA	-52.48M	-52.66M	-128.20M	-155.59M	-155.68M	-125.81M
Net Income	-69.89M	-70.81M	-113.87M	-165.46M	-158.09M	-130.09M
Balance Sheet
Total Assets	158.07M	245.96M	282.62M	328.92M	469.55M	451.14M
Cash, Cash Equivalents and Short-Term Investments	59.56M	151.60M	146.94M	204.60M	369.58M	368.22M
Total Debt	23.30M	74.21M	25.23M	23.08M	25.47M	23.71M
Total Liabilities	195.50M	234.11M	243.10M	247.04M	263.58M	109.92M
Stockholders Equity	-37.43M	11.85M	39.51M	81.88M	205.96M	341.23M
Cash Flow
Free Cash Flow	-110.22M	-75.93M	-145.76M	-171.51M	1.95M	-56.50M
Operating Cash Flow	-107.86M	-73.21M	-140.88M	-141.77M	10.73M	-53.59M
Investing Cash Flow	-17.44M	-58.95M	176.54M	89.14M	75.80M	-278.92M
Financing Cash Flow	24.19M	78.75M	880.00K	12.87M	3.29M	340.05M

Adaptimmune Therapeutics Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 0.29
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ADAP, the sentiment is Neutral. The current price of 0.29 is above the 20-day moving average (MA) of 0.26, above the 50-day MA of 0.27, and below the 200-day MA of 0.48, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 60.35 is Neutral, neither overbought nor oversold. The STOCH value of 67.15 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for ADAP.

Adaptimmune Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	65 Neutral	€6.38B	19.21	-1.30%	2.25%	-0.15%	-41.88%
ADAP	47 Neutral	$70.42M	―	-273.36%	―	883.05%	62.93%
ADAG	44 Neutral	$90.77M	―	-55.14%	―	-99.43%	-69.40%
CLSD	43 Neutral	$27.31M	―	91.63%	―	-55.47%	24.92%
CABA	39 Underperform	$142.11M	―	-73.85%	―	―	-40.59%
CNTX	37 Underperform	$74.45M	―	-55.59%	―	―	65.02%
JSPR	35 Underperform	$47.32M	―	-101.34%	―	―	21.40%

Adaptimmune Therapeutics Corporate Events

Adaptimmune Settles Litigation with M.D. Anderson Cancer Center

On July 16, 2025, Adaptimmune Therapeutics plc entered into a settlement agreement with The University of Texas M.D. Anderson Cancer Center to resolve litigation related to a Strategic Alliance Agreement from 2016. The settlement, which involves financial payment obligations, is not expected to have a material adverse effect on Adaptimmune’s financial position or operations.

The most recent analyst rating on (ADAP) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Adaptimmune Therapeutics stock, see the ADAP Stock Forecast page.

Adaptimmune’s Annual Meeting Focuses on Shareholder Engagement

Adaptimmune Therapeutics held its annual general meeting on May 29, 2025, where shareholders voted on several resolutions, including the re-election of directors and the approval of the company’s 2025 Employee and Non-Employee Share Option Schemes. The meeting also determined that advisory votes on executive compensation will be held annually until 2031, reflecting the company’s commitment to shareholder engagement and governance practices.

The most recent analyst rating on (ADAP) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Adaptimmune Therapeutics stock, see the ADAP Stock Forecast page.